2023
A phase 2 expansion study of ARV-766, a PROTAC androgen receptor (AR) degrader, in metastatic castration-resistant prostate cancer (mCRPC).
Petrylak D, Stewart T, Gao X, Berghorn E, Lu H, Chan E, Gedrich R, Lang J, McKean M. A phase 2 expansion study of ARV-766, a PROTAC androgen receptor (AR) degrader, in metastatic castration-resistant prostate cancer (mCRPC). Journal Of Clinical Oncology 2023, 41: tps290-tps290. DOI: 10.1200/jco.2023.41.6_suppl.tps290.Peer-Reviewed Original ResearchMetastatic castration-resistant prostate cancerNovel hormonal agentsCohort expansionDisease progressionEastern Cooperative Oncology Group performance status scoreOngoing androgen deprivation therapyProstate-specific antigen (PSA) declineCastration-resistant prostate cancerGonadotropin-releasing hormone analogueCohort expansion studyAndrogen deprivation therapyPerformance status scoreOverall response ratePhase 1 portionWild-type ARDeprivation therapyPrior chemotherapyCurative optionDose escalationAvailable therapiesHormonal agentsStatus scoreCurrent therapiesLigand-binding domainClinical trials
2007
Taxane-Based Chemotherapy for Prostate Cancer
Mohile S, Petrylak D. Taxane-Based Chemotherapy for Prostate Cancer. Contemporary Cancer Research 2007, 445-462. DOI: 10.1007/978-1-59745-224-3_23.Peer-Reviewed Original ResearchHormone-refractory prostate cancerTreatment of HRPCProstate cancerProgressive hormone-refractory prostate cancerCastrate testosterone levelsTaxane-based chemotherapyTaxane-based therapyProgression of diseaseTAX 327Adjuvant treatmentMetastatic diseaseSurvival benefitClinical outcomesDisease complicationsDismal prognosisSignificant morbidityAvailable therapiesEndothelin receptorsTargeted therapyTestosterone levelsTreatment liesChemotherapeutic agentsDrug resistanceTherapyMinimal toxicity